Growth hormone secretagogue cjc1295 and Ipamorelin

About this episode

This episode discusses the mechanisms and clinical research surrounding growth hormone secretagogues CJC1295 and Ipamorelin.

This episode is designed for listeners interested in clinical research, peptide science, endocrinology, and translational medicine , offering an evidence-based perspective without speculation or medical advice. Topics include: Tesamorelin peptide mechanism of action Preclinical and animal studies Phase II and Phase III clinical trial data FDA approval and HIV-associated lipodystrophy Growth hormone, IGF-1, and metabolic effects Safety, limitations, and ongoing research

People in this episode

Host: Infinity Peptides

Topics covered

• clinical research
• peptide science
• endocrinology
• translational medicine
• growth hormone
• metabolic effects
• safety and limitations

Keywords

• BPC 157
• CJC1295
• Ipamorelin
• Tesamorelin
• clinical trials
• FDA approval
• HIV-associated lipodystrophy
• growth hormone
• IGF-1
• metabolic effects

Mentioned in this episode

Organizations: FDA

Products: BPC 157 Peptide, CJC1295, Ipamorelin, Tesamorelin

More episodes of Today's discussion

• Pinealon: The Science and Hype of Brain Bioregulators · September 8, 2026 · 21 min
• Dulaglutide: The Foundation of Modern Metabolic Medicine · August 31, 2026 · 21 min
• FOXO4-DRI: The Science and Hype of Senolytic Peptides · August 24, 2026 · 26 min
• Cerebrolysin: Clinical Science and Biohacking Analysis · August 17, 2026 · 23 min
• ADAMAX Peptide: Science, Hype, and Cognitive Potential · August 10, 2026 · 19 min
• Survodutide: The Metabolic Power of Dual Receptor Agonism · August 3, 2026 · 20 min